(Q44038912)

29 November 2017

title

Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation (English)

1 reference

29 November 2017

L Hambach

1

1 reference

29 November 2017

M Stadler

2

1 reference

29 November 2017

E Dammann

3

1 reference

29 November 2017

A Ganser

4

1 reference

29 November 2017

B Hertenstein

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Bone Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

29

1 reference

29 November 2017

issue

11

1 reference

29 November 2017

page(s)

903-906

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703583

29 November 2017

exact match

0 references

cites work

Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703583

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703583

1 reference

Dimensions Publication ID

29 November 2017

1021016974

0 references

1 reference